

Boris Zelkind (State Bar No. 214,014)  
[boris.zelkind@kmob.com](mailto:boris.zelkind@kmob.com)  
Erik T. Anderson (State Bar No. 216,457)  
[erik.anderson@kmob.com](mailto:erik.anderson@kmob.com)  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
550 West C Street, Suite 1200  
San Diego, CA 92101  
Phone: (619) 235-8550  
Facsimile: (619) 235-0176

Donald R. Ware (*pro hac vice* pending)  
[dware@foleyhoag.com](mailto:dware@foleyhoag.com)  
Barbara A. Fiacco (*pro hac vice* pending)  
[bfiacco@foleyhoag.com](mailto:bfiacco@foleyhoag.com)  
Brian C. Carroll (*pro hac vice* pending)  
[bcarroll@foleyhoag.com](mailto:bcarroll@foleyhoag.com)  
FOLEY HOAG LLP  
155 Seaport Boulevard  
Boston, MA 02210  
Phone: (617) 832-100  
Facsimile: (617) 832-7000

Attorneys for Defendant  
BECTON, DICKINSON AND COMPANY

IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF CALIFORNIA

GEN-PROBE INCORPORATED	)	Case No. 09cv2319 BEN (NLS)
	)	
Plaintiff,	)	<b>ANSWER AND COUNTERCLAIM OF</b>
	)	<b>DEFENDANT BECTON, DICKINSON</b>
v.	)	<b>AND COMPANY</b>
	)	
BECTON, DICKINSON AND COMPANY	)	
	)	
Defendant.	)	<b>JURY TRIAL DEMANDED</b>
	)	
	)	

1 Defendant Becton, Dickinson and Company (“BD”) hereby responds to the numbered  
2 paragraphs of the Complaint of plaintiff Gen-Probe Incorporated (“Gen-Probe”) as follows:

3 1. Paragraph 1 is an introductory statement that does not require any response. To  
4 the extent a response is required, BD denies the allegations set forth in paragraph 1 except that  
5 BD admits that Gen-Probe markets equipment and nucleic acid tests for the detection of  
6 Chlamydia trachomatis and Neisseria gonorrhoeae.

7 **THE PARTIES**

8 2. BD lacks knowledge or information sufficient to form a belief as to the truth or  
9 falsity of the allegations set forth in paragraph 2, and on that basis denies the allegations.

10 3. BD admits the allegations of paragraph 3.

11 4. BD admits that the Gen-Probe TIGRIS System is being used in some clinical  
12 laboratories for diagnosis of diseases including Chlamydia trachomatis and Neisseria  
13 gonorrhoeae. BD lacks knowledge or information sufficient to form a belief as to the truth or  
14 falsity of the remaining allegations set forth in paragraph 4, and on that basis denies the  
15 allegations.

16 **JURISDICTION AND VENUE**

17 5. BD admits the allegations of paragraph 5.

18 6. BD admits that it has a regular place of business and that it transacts business  
19 within this judicial district. BD denies all remaining allegations of paragraph 6.

20 **BACKGROUND**

21 7. BD admits the allegations of paragraph 7.

22 8. BD admits the allegations of paragraph 8.

23 9. BD admits the allegations of paragraph 9.

24 10. BD admits the allegations of paragraph 10.

25 11. BD admits the allegations of paragraph 11.

26 12. BD admits the allegations of paragraph 12.

27 13. BD admits the allegations of paragraph 13.

28 14. BD admits the allegations of paragraph 14.

1           15.     BD lacks knowledge or information sufficient to form a belief as to the truth or  
2     falsity of the allegations set forth in paragraph 15, and on that basis denies the allegations.

3                           **COUNT ONE (THE '256 PATENT)**

4           16.     BD repeats and incorporates herein its responses to paragraphs 1 through 15.

5           17.     BD denies that it has practiced or infringed, or is practicing or infringing, directly  
6     or indirectly, any claim of United States Patent No. 7,560,256 (“the ’256 patent”). BD admits  
7     that it has actual knowledge of the ’256 patent. BD admits that it manufactures and distributes a  
8     product called the “BD Viper™ System with XTR™ Technology” and that it provides written  
9     information to customers concerning the use of that product. BD denies all remaining  
10    allegations of paragraph 17.

11          18.     BD denies the allegations of paragraph 18.

12          19.     BD denies the allegations of paragraph 19.

13                           **COUNT TWO (THE '255 PATENT)**

14          20.     BD repeats and incorporates herein its responses to paragraphs 1 through 15.

15          21.     BD denies that it has practiced or infringed, or is practicing or infringing, directly  
16     or indirectly, any claim of United States Patent No. 7,560,255 (“the ’255 patent”). BD admits  
17     that it has actual knowledge of the ’255 patent. BD admits that it manufactures and distributes a  
18     product called the “BD Viper™ System with XTR™ Technology” and that it provides written  
19     information to customers concerning the use of that product. BD denies all remaining  
20    allegations of paragraph 21.

21          22.     BD denies the allegations of paragraph 22.

22          23.     BD denies the allegations of paragraph 23.

23                           **COUNT THREE (THE '652 PATENT)**

24          24.     BD repeats and incorporates herein its responses to paragraphs 1 through 15.

25          25.     BD denies that it has practiced or infringed, or is practicing or infringing, directly  
26     or indirectly, any claim of United States Patent No. 7,524,652 (“the ’652 patent”). BD admits  
27     that it has actual knowledge of the ’652 patent. BD admits that it manufactures and distributes a  
28     product called the “BD Viper™ System with XTR™ Technology” and that it provides written

1 information to customers concerning the use of that product. BD denies all remaining  
2 allegations of paragraph 25.

3 26. BD denies the allegations of paragraph 26.

4 27. BD denies the allegations of paragraph 27.

5 **COUNT FOUR (THE '143 PATENT)**

6 28. BD repeats and incorporates herein its responses to paragraphs 1 through 15.

7 29. BD denies that it has practiced or infringed, or is practicing or infringing, directly  
8 or indirectly, any claim of United States Patent No. 7,482,143 ("the '143 patent"). BD admits  
9 that it has actual knowledge of the '143 patent. BD admits that it manufactures and distributes a  
10 product called the "BD Viper™ System with XTR™ Technology" and that it provides written  
11 information to customers concerning the use of that product. BD denies all remaining  
12 allegations of paragraph 29.

13 30. BD denies the allegations of paragraph 30.

14 31. BD denies the allegations of paragraph 31.

15 **COUNT FIVE (THE '892 PATENT)**

16 32. BD repeats and incorporates herein its responses to paragraphs 1 through 15.

17 33. BD denies that it has practiced or infringed, or is practicing or infringing, directly  
18 or indirectly, any claim of United States Patent No. 7,118,892 ("the '892 patent"). BD admits  
19 that it has actual knowledge of the '892 patent. BD admits that it manufactures and distributes a  
20 product called the "BD Viper™ System with XTR™ Technology" and that it provides written  
21 information to customers concerning the use of that product. BD denies all remaining  
22 allegations of paragraph 33.

23 34. BD denies the allegations of paragraph 34.

24 35. BD denies the allegations of paragraph 35.

25 **COUNT SIX (THE '200 PATENT)**

26 36. BD repeats and incorporates herein its responses to paragraphs 1 through 15.

27 37. BD denies that it has practiced or infringed, or is practicing or infringing, directly  
28 or indirectly, any claim of United States Patent No. 5,612,200 ("the '200 patent"). BD admits

1 that it has actual knowledge of the '200 patent. BD admits that it manufactures and distributes  
2 products called the "BD Viper System™" and "BD Viper™ System with XTR™ Technology"  
3 and that it provides written information to customers concerning the use of those products. BD  
4 denies all remaining allegations of paragraph 37.

5 38. BD denies the allegations of paragraph 38.

6 39. BD denies the allegations of paragraph 39.

7 **COUNT SEVEN (THE '308 PATENT)**

8 40. BD repeats and incorporates herein its responses to paragraphs 1 through 15.

9 41. BD denies that it has practiced or infringed, or is practicing or infringing, directly  
10 or indirectly, any claim of United States Patent No. 7,294,308 ("the '308 patent"). BD admits  
11 that it has actual knowledge of the '308 patent. BD admits that it manufactures, distributes and  
12 sells products called the "Female Endocervical Specimen Collection Kit for BD ProbeTec™  
13 CT/GC Q<sup>x</sup> Amplified DNA Assays" and "Male Urethral Specimen Collection Kit for BD  
14 ProbeTec™ CT/GC Q<sup>x</sup> Amplified DNA Assays" and that it provides written information to  
15 customers concerning the use of those products. BD denies all remaining allegations of  
16 paragraph 41.

17 42. BD denies the allegations of paragraph 42.

18 43. BD denies the allegations of paragraph 43.

19 **COUNT EIGHT (THE '612 PATENT)**

20 44. BD repeats and incorporates herein its responses to paragraphs 1 through 15.

21 45. BD denies that it has practiced or infringed, or is practicing or infringing, directly  
22 or indirectly, any claim of United States Patent No. 6,893,612 ("the '612 patent"). BD admits  
23 that it has actual knowledge of the '612 patent. BD admits that it manufactures, distributes and  
24 sells products called the "Female Endocervical Specimen Collection Kit for BD ProbeTec™  
25 CT/GC Q<sup>x</sup> Amplified DNA Assays" and "Male Urethral Specimen Collection Kit for BD  
26 ProbeTec™ CT/GC Q<sup>x</sup> Amplified DNA Assays" and that it provides written information to  
27 customers concerning the use of those products. BD denies all remaining allegations of  
28 paragraph 45.

1 46. BD denies the allegations of paragraph 46.

2 47. BD denies the allegations of paragraph 47.

3 **AFFIRMATIVE DEFENSES**

4 **First Defense**

5 The claims of United States Patent No. 7,560,256 (“the ’256 patent”) are invalid for  
6 failure to comply with the conditions and requirements for patentability set forth in one or more  
7 of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
8 patenting.

9 **Second Defense**

10 The claims of United States Patent No. 7,560,255 (“the ’255 patent”) are invalid for  
11 failure to comply with the conditions and requirements for patentability set forth in one or more  
12 of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
13 patenting.

14 **Third Defense**

15 The claims of United States Patent No. 7,524,652 (“the ’652 patent”) are invalid for  
16 failure to comply with the conditions and requirements for patentability set forth in one or more  
17 of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
18 patenting.

19 **Fourth Defense**

20 The claims of United States Patent No. 7,482,143 (“the ’143 patent”) are invalid for  
21 failure to comply with the conditions and requirements for patentability set forth in one or more  
22 of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
23 patenting.

24 **Fifth Defense**

25 The claims of United States Patent No. 7,118,892 (“the ’892 patent”) are invalid for  
26 failure to comply with the conditions and requirements for patentability set forth in one or more  
27 of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
28 patenting.

**Sixth Defense**

The claims of United States Patent No. 5,612,200 (“the ’200 patent”) are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112.

**Seventh Defense**

The claims of United States Patent No. 7,294,308 (“the ’308 patent”) are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**Eighth Defense**

The claims of United States Patent No. 6,893,612 (“the ’612 patent”) are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**Ninth Defense**

Gen-Probe is not entitled to relief against BD because BD is not practicing or infringing, and has not practiced or infringed, either directly or indirectly, any valid claim of the ’256 patent, ’255 patent, ’652 patent, ’143 patent, ’892 patent, ’200 patent, ’308 patent, or ’612 patent.

**Tenth Defense**

Some or all of Gen-Probe’s claims for relief are barred by the doctrines of waiver, laches, and/or estoppel, including but not limited to estoppel based on representations to the United States Patent and Trademark Office during prosecution of the ’256 patent, ’255 patent, ’652 patent, ’143 patent, ’892 patent, ’200 patent, ’308 patent, and/or ’612 patent.

**Eleventh Defense**

Some or all of the accused acts are exempt from liability under 35 U.S.C. § 271(e)(1).

**Twelfth Defense**

On information and belief, Gen-Probe’s claims for damages are limited by the provisions of 35 U.S.C. § 287.

**Thirteenth Defense**

Some or all of Gen-Probe's claims for relief are barred by the doctrine of unclean hands.

**COUNTERCLAIMS OF BECTON, DICKINSON AND COMPANY**

Becton, Dickinson and Company ("BD"), for its Counterclaim against Gen-Probe Incorporated ("Gen-Probe"), alleges as follows:

**PARTIES, JURISDICTION AND VENUE**

1. BD, the Counterclaimant in this Counterclaim, is a New Jersey corporation having a principal place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417.

2. Gen-Probe, the Counterdefendant in this Counterclaim, has alleged that it is a Delaware corporation having a principal place of business at 10210 Genetic Center Drive, San Diego, California 92121.

3. There is an actual dispute and controversy between the parties as to whether the claims of the patents asserted in Gen-Probe's Complaint are valid.

4. This Court has jurisdiction over this Counterclaim pursuant to 28 U.S.C. §§ 1331, 1338(a), 1376, and 2201. Venue is proper under 28 U.S.C. §§ 1391 and 1400(b), and by Counterdefendant's choice of forum.

**COUNT ONE**

**Declaratory Judgment of Invalidity ('256 patent)**

5. The claims of United States Patent No. 7,560,256 ("the '256 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**COUNT TWO**

**Declaratory Judgment of Invalidity ('255 patent)**

6. The claims of United States Patent No. 7,560,255 ("the '255 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.



**COUNT THREE**

Declaratory Judgment of Invalidity ('652 patent)

7. The claims of United States Patent No. 7,524,652 ("the '652 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**COUNT FOUR**

Declaratory Judgment of Invalidity ('143 patent)

8. The claims of United States Patent No. 7,482,143 ("the '143 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**COUNT FIVE**

Declaratory Judgment of Invalidity ('892 patent)

9. The claims of United States Patent No. 7,118,892 ("the '892 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double patenting.

**COUNT SIX**

Declaratory Judgment of Invalidity ('200 patent)

10. The claims of United States Patent No. 5,612,200 ("the '200 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or more of 35 U.S.C. §§ 101, 102, 103 or 112.

**COUNT SEVEN**

Declaratory Judgment of Invalidity ('308 patent)

11. The claims of United States Patent No. 7,294,308 ("the '308 patent") are invalid for failure to comply with the conditions and requirements for patentability set forth in one or

1 more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
2 patenting.

3 **COUNT EIGHT**

4 **Declaratory Judgment of Invalidity ('612 patent)**

5 12. The claims of United States Patent No. 6,893,612 ("the '612 patent") are invalid  
6 for failure to comply with the conditions and requirements for patentability set forth in one or  
7 more of 35 U.S.C. §§ 101, 102, 103, or 112 and/or under the doctrine of obviousness-type double  
8 patenting.

9 **JURY DEMAND**

10 Pursuant to Fed R. Civ. P. 38(b), BD requests a trial by jury with respect to Gen-  
11 Probe's claims and BD's counterclaims.

12 **WHEREFORE**, BD respectfully requests the following relief:

- 13 A. That the Court enter judgment in favor of BD on all counts of Gen-Probe's  
14 Complaint;
- 15 B. That Gen-Probe's Complaint be dismissed with prejudice;
- 16 C. That the Court enter judgment in favor of BD on all counts of BD's Counterclaim;
- 17 D. That the claims of United States Patent No. 7,560,256 be declared invalid;
- 18 E. That the claims of United States Patent No. 7,560,255 be declared invalid;
- 19 F. That the claims of United States Patent No. 7,524,652 be declared invalid;
- 20 G. That the claims of United States Patent No. 7,482,143 be declared invalid;
- 21 H. That the claims of United States Patent No. 7,118,892 be declared invalid;
- 22 I. That the claims of United States Patent No. 5,612,200 be declared invalid;
- 23 J. That the claims of United States Patent No. 7,294,308 be declared invalid;
- 24 K. That the claims of United States Patent No. 6,893,612 be declared invalid;
- 25 L. That BD be awarded all its costs and disbursements in this action, together with  
26 its attorneys' fees incurred herein; and

27 ///

28 ///

1 M. That this Court order such other and further relief as this Court deems just and  
2 proper.

3  
4 Respectfully submitted,

5 KNOBBE, MARTENS, OLSON & BEAR, LLP  
6

7 Dated: December 9, 2009

By: s/Erik T. Anderson

8 Boris Zelkind

Erik T. Anderson

9 and

10 FOLEY HOAG LLP

11 Donald R. Ware (*pro hac vice* pending)

Barbara A. Fiacco (*pro hac vice* pending)

12 Brian C. Carroll (*pro hac vice* pending)

13 Attorneys for Defendant

14 BECTON, DICKINSON AND COMPANY  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**CERTIFICATE OF SERVICE**

I hereby certify that on December 9, 2009 I caused the **ANSWER AND COUNTERCLAIM OF DEFENDANT BECTON, DICKINSON AND COMPANY** to be electronically filed with the Clerk of the Court using the CM/ECF system which will send electronic notification of such filing to the following person(s):


Stephen P. Swinton  
LATHAM & WATKINS LLP  
[steve.swinton@lw.com](mailto:steve.swinton@lw.com)

Mark A. Finkelstein  
LATHAM & WATKINS LLP  
[mark.finkelstein@lw.com](mailto:mark.finkelstein@lw.com)

Alexander Long  
LATHAM & WATKINS LLP  
[alex.long@lw.com](mailto:alex.long@lw.com)

I certify and declare under penalty of perjury under the laws of the State of California that I am employed in the office of a member of the bar of this Court at whose direction the service was made, and that the forgoing is true and correct.

Executed on December 9, 2009, at San Diego, California.

  
Megan Ptacin

8225897  
120809